Genzyme Corporation

États‑Unis d’Amérique


 
Quantité totale PI 1 216
Quantité totale incluant filiales 1 218 (+ 2 pour les filiales)
Rang # Quantité totale PI 1 087
Note d'activité PI 3,5/5.0    720
Rang # Activité PI 1 002
Parent Sanofi
Classe Nice dominante Produits pharmaceutiques, vétéri...

Brevets

Marques

433 75
150 70
331 13
144
 
Dernier brevet 2025 - Fluid transfer device
Premier brevet 1976 - Production of uricase from micro...
Dernière marque 2024 - HEMASSIST SANOFI PATIENT SUPPORT
Première marque 1969 - LYMPHOGLOBULINE

Filiales

5 subsidiaries with IP (1 patents, 1 trademarks)

28 subsidiaries without IP

 S'inscrire grtuitement pour accéder à la liste des filiales

Industrie (Classification de Nice)

Derniers inventions, produits et services

2024 Invention Systems and devices for producing biological products and methods of using the same. Systems and...
P/S Downloadable software in the nature of a mobile application for enabling users to enter, access, ...
Invention Process for preparing shp2 inhibitors. Provided herein are methods for preparing a SHP2 inhibito...
Invention Perfusion bioreactor with filtration systems. The disclosure provides a filtration system for a ...
P/S Pharmaceutical preparations for the prevention and treatment of cardiovascular diseases and disea...
Invention Integrated continuous manufacturing of therapeutic protein drug substances. Provided herein are ...
Invention Methods for detecting aav. Provided herein are methods for determining the serotype of a virus p...
Invention Analytical ultracentrifugation for characterization of recombinant viral particles. Provided her...
Invention Methods of controlling the formation of disulfide bonds in protein solutions. Disclosed herein a...
Invention Glucosylceramide synthase inhibitors. The invention relates to inhibitors of glucosylceramide sy...
Invention Treatment of cancer with anti-ilt2 antibodies. The present invention relates to treatment of can...
Invention Treatment of cancer with anti-ilt2 antibodies. The present invention relates to treatment of canc...
Invention Substituted cyclic compounds and methods of treating phenylketonuria and other amino acidurias. T...
Invention Process for preparing 4-(3,3-difluoro-2,2-dimethyl-propanoyl)-3,5-dihydro-2h-pyrido[3,4-f][l,4]ox...
Invention Sleep-wake classification using machine learning. Methods, systems, and apparatus, including comp...
Invention Treatment of multiple sclerosis with anti-cd40l antibodies. The present invention relates to tre...
Invention Treatment of multiple sclerosis with anti-cd40l antibodies. The present invention relates to trea...
Invention Fluid transfer device. A fluid transfer device for transferring a fluid between a diluent contain...
Invention Fluid transfer device. A fluid transfer device includes a body, a first connecting portion compri...
Invention Fluid transfer device. A fluid transfer device includes a body having a first connecting portion ...
Invention Predicting motor function scores in pompe disease treatment. A prediction method for predicting a...
Invention Drug formulations of 4-(3,3-difluoro-2,2-dimethyl-propanoyl) -3,5-dihydro-2h-pyrido[3,4-f][1,4]ox...
Invention Isoxazolidines as ripk1 inhibitors and use thereof. 14141414,14222222, or a pharmaceutically acce...
Invention Isoxazolidines as ripk1 inhibitors and use thereof. 1236127103144143456166)alkyl group or a halog...
Invention Isoxazolidines as ripk1 inhibitors and use thereof. 14141414,142 14321414221414363636366)heterocy...
Invention Perfusion culturing methods and uses thereof. Provided herein are methods of culturing a mammali...
Invention Parkinson's tremor classification using machine learning. Methods, systems, and apparatus, includ...
Invention Marker for acid sphingomyelinase disorders and uses thereof. The present disclosure provides met...
Invention Methods of improving raav production. This disclosure relates to methods and compositions for sc...
Invention Methods of improving raav production. This disclosure relates to methods and compositions for sca...
Invention Humanized anti-complement factor bb antibodies and uses thereof. Provided herein are humanized a...
Invention Targeted gene therapy for dm-1 myotonic dystrophy. Provided herein are RNAi molecules for treati...
Invention Scfv-fc dimers that bind transforming growth factor-beta1 with high affinity, avidity and specifi...
Invention Targeted gene therapy for dm-1 myotonic dystrophy. e.g., e.g., rAAV), viral particles, and pharma...
Invention Devices for cell lysis and methods of use thereof. Provided herein are methods for isolating intr...
Invention Gene therapy for neurodegenerative disorders. Compositions and methods for treating disorders af...
Invention Treatment of dry age-related macular degeneration. The present disclosure provides gene therapy ...
Invention Treatment of dry age-related macular degeneration. The present disclosure provides gene therapy t...
Invention Nbd1 modulators and methods of using the same. The present disclosure includes, among other thing...
Invention Indole compounds and methods of use. The invention relates to heterocyclic compounds, pharmaceut...
Invention Automated screening for acid sphingomyelinase deficiency. Methods, systems, and apparatus, includ...
Invention Hsc-specific antibody conjugated lipid nanoparticles and uses thereof. Provided are ionizable cat...
Invention Assays for detecting the presence or amount of an anti-drug antibody. Methods and kits for detec...
Invention Drug formulations of 4-(3,3-difluoro-2,2-dimethyl-propanoyl)-3,5-dihydro-2h-pyrido [3,4-f] [1,4] ...
Invention Recombinant aav vectors expressing osteoprotective genes, including has2 and lubricin, useful in ...
2023 Invention Anti-pd-1×4-1bb binding proteins. Anti-4-1BB and anti-PD-1 binding proteins, as well as bispecif...
P/S Pharmaceutical products for the prevention and treatment of immunological diseases; pharmaceutica...
P/S Pharmaceutical products for the prevention and treatment of immunological diseases, pharmaceutica...
Invention Methods for purification of recombinant aav vectors. Provided herein are methods for the purific...
P/S Pharmaceuticals for use in the treatment of lysosomal storage diseases
P/S Support services for patients and caregivers in the field of rare genetic diseases and disorders,...
P/S Pharmaceutical preparations for the treatment of autosomal dominant polycystic kidney disease; ph...
2022 P/S Pharmaceutical preparations for the treatment of hemophilia. Downloadable mobile application in t...
P/S Pharmaceutical preparations for the treatment of rare diseases notably lysosomal storage disorders.
Invention Novel predictive biomarkers for secondary autoimmunity after lymphocyte depleting therapy. The i...